Lineage Cell Therapeutics, Inc.
WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
53566P109
SEDOL
N/A
CIK
0000876343
www.lineagecell.com
LEI:
FIGI: BBG000G8RJY6
LCTX
Lineage Cell Therapeutics, Inc.
GICS: -
·
Sector: Healthcare
·
Sub-Sector: Biotechnology
NAME
Lineage Cell Therapeutics, Inc.
ISIN
US53566P1093
TICKER
LCTX
MIC
XASE
REUTERS
LCTX.N
BLOOMBERG
LCTX US
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Mon, 06.01.2025
Lineage Cell Therapeutics
US53566P1093
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today published a letter to shareholders highlighting the company’s recent achievements and outlook for 2025.
Dear Fellow Shareholders,
We hope you had a restful holiday season and...
Lineage Cell Therapeutics
Thu, 21.11.2024
Lineage Cell Therapeutics
US53566P1093
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the first closing of its previously announced registered direct offering for the purchase and sale of up to an aggregate of 39,473,688 of Lineage’s common shares and ac...
Lineage Cell Therapeutics
Wed, 20.11.2024
Lineage Cell Therapeutics
US53566P1093
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it entered into definitive agreements with certain healthcare focused institutional investors and with Broadwood Partners, L.P. (“Broadwood”), an affiliate of Neal...
Lineage Cell Therapeutics
Thu, 14.11.2024
Lineage Cell Therapeutics
US53566P1093
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its third quarter 2024 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a...
Lineage Cell Therapeutics
Thu, 07.11.2024
Lineage Cell Therapeutics
US53566P1093
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, following the close of the U.S. financial markets. Lineage ma...
Lineage Cell Therapeutics
Mon, 14.10.2024
Lineage Cell Therapeutics
US53566P1093
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the Maxim Group 2024 Virtual Healthcare Summit, in a fireside chat hosted by Jason McCart...
Lineage Cell Therapeutics
Wed, 25.09.2024
Lineage Cell Therapeutics
US53566P1093
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Sy...
Lineage Cell Therapeutics
Wed, 18.09.2024
Lineage Cell Therapeutics
US53566P1093
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported that preclinical results with ReSonance (ANP1), the Company’s auditory neuronal cell transplant for the treatment of hearing loss, were presented at the 59th Annual Inne...
Lineage Cell Therapeutics
Tue, 13.08.2024
Lineage Cell Therapeutics
US53566P1093
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference being held on Thursday, A...
Lineage Cell Therapeutics
Thu, 08.08.2024
Lineage Cell Therapeutics
US53566P1093
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its second quarter 2024 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide ...
Lineage Cell Therapeutics
Information on product placements
SMART * AD
P R O D U C T S U G G E S T I O N S
